Lonza completed validation of viral-induced cell processing GMP suites and completed the tech transfer process.
Lonza viral-based therapeutics head David Enloe said, "We are pleased to have been selected by our existing viral vector client to additionally perform the development and manufacture of virally-modified cellular products to support its clinical studies."
The company previously expanded the GMP facilities in Houston to add various cell processing suites.